News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
316,006 Results
Type
Article (16013)
Company Profile (37)
Press Release (299951)
Multimedia
Podcasts (48)
Webinars (5)
Section
Business (81013)
Career Advice (1353)
Deals (16119)
Drug Delivery (48)
Drug Development (48803)
Employer Resources (55)
FDA (7929)
Job Trends (6565)
News (152330)
Policy (12678)
Tag
2027 Biotech Bay Standard (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (1039)
Accelerated approval (34)
Adcomms (17)
Allergies (120)
Alliances (15332)
ALS (143)
Alzheimer's disease (999)
Antibody-drug conjugate (ADC) (362)
Approvals (8370)
Artificial intelligence (402)
Autoimmune disease (231)
Automation (31)
Bankruptcy (118)
Best Places to Work (5668)
BIOSECURE Act (4)
Biosimilars (155)
Biotechnology (25)
Bladder cancer (181)
Brain cancer (59)
Breast cancer (614)
Cancer (4469)
Cardiovascular disease (369)
Career advice (1069)
Career pathing (20)
CAR-T (198)
CDC (21)
Celiac Disease (2)
Cell therapy (548)
Cervical cancer (33)
Clinical research (46086)
Collaboration (1295)
Company closure (4)
Compensation (928)
Complete response letters (57)
COVID-19 (1311)
CRISPR (67)
C-suite (584)
Cystic fibrosis (80)
Data (6377)
Decentralized trials (1)
Denatured (1)
Depression (110)
Dermatology (74)
Diabetes (412)
Diagnostics (3076)
Digital health (34)
Diversity (2)
Diversity, equity & inclusion (11)
Drug discovery (198)
Drug pricing (67)
Drug shortages (11)
Duchenne muscular dystrophy (212)
Earnings (55162)
Editorial (23)
Employer branding (8)
Employer resources (48)
Events (52559)
Executive appointments (610)
FDA (10706)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (10)
Frontotemporal dementia (24)
Funding (1083)
Gene editing (144)
Generative AI (26)
Gene therapy (472)
GLP-1 (700)
Government (1791)
Grass and pollen (6)
Guidances (381)
Healthcare (8289)
HIV (64)
Huntington's disease (42)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (80)
Immunology and inflammation (186)
Immuno-oncology (73)
Indications (154)
Infectious disease (1546)
Inflammatory bowel disease (144)
Inflation Reduction Act (8)
Influenza (98)
Intellectual property (162)
Interviews (254)
IPO (9751)
IRA (16)
Job creations (1198)
Job search strategy (918)
JPM (26)
Kidney cancer (19)
Labor market (64)
Layoffs (273)
Leadership (24)
Legal (2065)
Liver cancer (76)
Longevity (14)
Lung cancer (609)
Lymphoma (368)
Machine learning (35)
Management (17)
Manufacturing (518)
MASH (171)
Medical device (6208)
Medtech (6284)
Mergers & acquisitions (7215)
Metabolic disorders (1078)
mRNA (92)
Multiple sclerosis (149)
NASH (18)
Neurodegenerative disease (300)
Neuropsychiatric disorders (79)
Neuroscience (2050)
NextGen: Class of 2026 (2423)
Non-profit (2124)
Now hiring (16)
Obesity (481)
Opinion (125)
Ovarian cancer (161)
Pain (172)
Pancreatic cancer (234)
Parkinson's disease (250)
Partnered (8)
Patents (311)
Patient recruitment (468)
Peanut (46)
People (14668)
Pharmaceutical (14)
Pharmacy benefit managers (13)
Phase 1 (11611)
Phase 2 (18978)
Phase 3 (19464)
Pipeline (7157)
Policy (101)
Postmarket research (1378)
Preclinical (4000)
Press Release (18)
Prostate cancer (244)
Psychedelics (28)
Radiopharmaceuticals (178)
Rare diseases (735)
Real estate (1569)
Recruiting (22)
Regulatory (12328)
Reports (35)
Research institute (980)
Resumes & cover letters (259)
Rett syndrome (33)
RNA editing (13)
RSV (69)
Schizophrenia (146)
Series A (158)
Series B (127)
Service/supplier (4)
Sickle cell disease (82)
Special edition (25)
Spinal muscular atrophy (120)
Sponsored (25)
Startups (1117)
Stomach cancer (9)
Supply chain (68)
Tariffs (37)
The Weekly (47)
Vaccines (609)
Venture capital (64)
Weight loss (301)
Women's health (81)
Worklife (11)
Date
Today (71)
Last 7 days (480)
Last 30 days (2535)
Last 365 days (21281)
2026 (9034)
2025 (21447)
2024 (20532)
2023 (21229)
2022 (25568)
2021 (26883)
2020 (25279)
2019 (20186)
2018 (15167)
2017 (15632)
2016 (13556)
2015 (16128)
2014 (11829)
2013 (8845)
2012 (9257)
2011 (9743)
2010 (8375)
Location
Africa (388)
Alabama (39)
Alaska (3)
Arizona (96)
Arkansas (10)
Asia (22073)
Australia (4120)
California (9513)
Canada (2277)
China (982)
Colorado (375)
Connecticut (423)
Delaware (318)
Europe (46232)
Florida (1148)
Georgia (261)
Hawaii (3)
Idaho (21)
Illinois (725)
India (52)
Indiana (369)
Iowa (11)
Japan (487)
Kansas (73)
Kentucky (19)
Louisiana (31)
Maine (47)
Maryland (917)
Massachusetts (6621)
Michigan (146)
Minnesota (431)
Mississippi (6)
Missouri (90)
Montana (12)
Nebraska (8)
Nevada (105)
New Hampshire (50)
New Jersey (2549)
New Mexico (10)
New York (2369)
North Carolina (1094)
North Dakota (5)
Northern California (4891)
Ohio (230)
Oklahoma (7)
Oregon (17)
Pennsylvania (1726)
Puerto Rico (14)
Rhode Island (21)
South America (555)
South Carolina (38)
Southern California (3723)
Tennessee (119)
Texas (1456)
United States (31646)
Utah (209)
Virginia (233)
Washington D.C. (37)
Washington State (728)
West Virginia (2)
Wisconsin (114)
Wyoming (1)
316,006 Results for "3".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B
Right after reporting a major Phase 3 LAG-3 miss that has rattled analysts, Regeneron Pharmaceuticals revealed a back-loaded partnership with Parabilis Medicines aimed at adding a new drug class to its early-stage pipeline.
May 18, 2026
·
2 min read
·
Gabrielle Masson
Cancer
Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3
The late-stage miss shakes analyst confidence in Regeneron’s clinical execution, according to BMO Capital Markets, also noting last year’s Phase 3 failure in chronic obstructive pulmonary disease.
May 18, 2026
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Viridian turns green again as new Phase 3 data vindicate thyroid eye disease drug
Viridian Therapeutics’ elegrobart normalized the degree of eye protrusion and improved double vision in a Phase 3 study. The company plans to file for approval in the first quarter of 2027.
May 6, 2026
·
1 min read
·
Tristan Manalac
Neurodegenerative disease
Corcept ties ALS drug to improved 2-year survival as Phase 3 start date nears
Corcept Therapeutics’ amyotrophic lateral sclerosis drug was linked to an 87% reduction in the risk of death, a result the biotech hopes to replicate in an upcoming Phase 3 trial.
May 1, 2026
·
2 min read
·
Nick Paul Taylor
Obesity
Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3
Topline Phase 3 results of survodutide—licensed to Boehringer Ingelheim from Zealand Pharma—are more comparable to Novo Nordisk’s Wegovy than to Eli Lilly’s Zepbound, William Blair analysts said on Tuesday.
April 28, 2026
·
2 min read
·
Heather McKenzie
Approvals
Travere’s Filspari overcomes Phase 3 fail to become first drug for rare kidney disease
The FDA has greenlit Travere Therapeutics’ Filspari as the only available treatment for focal segmental glomerulosclerosis despite the drug’s loss to Sanofi’s Avapro in a Phase 3 study.
April 14, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma
May 17, 2026
·
9 min read
Deals
Lilly lands third oncology deal in 3 weeks, inking up to $2.3B for Ajax
Eli Lilly is picking up Ajax Therapeutics and its once-daily oral blood cancer candidate. The deal follows the pharma’s buyouts of ADC specialist CrossBridge Bio and in vivo CAR T company Kelonia Therapeutics.
April 27, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
Combined General Meeting of June 3, 2026
May 14, 2026
·
3 min read
Weight loss
Regeneron’s Weight Loss Partner Hansoh Delivers Much-Needed Phase 3 Win in China
Hansoh’s olatorepatide achieved 19% weight loss at 48 weeks in a Phase 3 trial in China, handing partner Regeneron a glimmer of hope for a pipeline in desperate need of reinvigoration.
March 9, 2026
·
2 min read
·
Annalee Armstrong
1 of 31,601
Next
